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ABSTRACT
Rationale Vitamin D deﬁciency has been implicated as
a pathogenic factor in sepsis and intensive therapy unit
mortality but has not been assessed as a risk factor for
acute respiratory distress syndrome (ARDS). Causality of
these associations has never been demonstrated.
Objectives To determine if ARDS is associated with
vitamin D deﬁciency in a clinical setting and to
determine if vitamin D deﬁciency in experimental models
of ARDS inﬂuences its severity.
Methods Human, murine and in vitro primary alveolar
epithelial cell work were included in this study.
Findings Vitamin D deﬁciency (plasma 25(OH)D levels
<50 nmol/L) was ubiquitous in patients with ARDS and
present in the vast majority of patients at risk of
developing ARDS following oesophagectomy. In a
murine model of intratracheal lipopolysaccharide
challenge, dietary-induced vitamin D deﬁciency resulted
in exaggerated alveolar inﬂammation, epithelial damage
and hypoxia. In vitro, vitamin D has trophic effects on
primary human alveolar epithelial cells affecting >600
genes. In a clinical setting, pharmacological repletion of
vitamin D prior to oesophagectomy reduced the
observed changes of in vivo measurements of alveolar
capillary damage seen in deﬁcient patients.
Conclusions Vitamin D deﬁciency is common in
people who develop ARDS. This deﬁciency of vitamin D
appears to contribute to the development of the
condition, and approaches to correct vitamin D
deﬁciency in patients at risk of ARDS should be
developed.
Trial registration UKCRN ID 11994.
INTRODUCTION
Acute respiratory distress syndrome (ARDS) occurs
due to either direct or indirect proinﬂammatory
insults. However, only a proportion of at-risk
patients develop ARDS, with research suggesting
that genetic, age, social and other factors play a
role in determining who develops ARDS.1
More than 1 billion people worldwide are
believed to have vitamin D deﬁciency.2 Vitamin D
has important functions besides bone and calcium
homeostasis3 with cells of the innate and adaptive
immune system responding to vitamin D. Vitamin
D deﬁciency may therefore increase the risk of bac-
terial and viral infection.
Vitamin D deﬁciency is associated with an
increased risk of intensive care admission and mor-
tality in patients with pneumonia.4 Deﬁciency is
common in critically ill patients and associated
with adverse outcome.3 Gram-positive bacteria,
invasive pneumococcal disease and meningococcal
disease are more common when 25(OH)D3 levels
are low.5 Recent data from an Austrian study in
critically ill deﬁcient patients suggests that when
treatment with vitamin D is successful in raising
levels >75 nmol/L there is a mortality beneﬁt.6
Vitamin D may improve outcomes by reducing
both local and systemic inﬂammatory responses as a
result of modulating cytokine responses.7 In a mouse
model of lethal endotoxaemia, survival post intraven-
ous lipopolysaccharide (LPS) was signiﬁcantly poorer
in the vitamin D receptor knockout mice.8
Our aim was to deﬁne the prevalence and sever-
ity of vitamin D deﬁciency in patients with ARDS
and to establish whether vitamin D deﬁciency is a
risk factor for and/or a driver of the exaggerated
and persistent inﬂammation that is a hallmark of
ARDS. To achieve these aims, we employed transla-
tional clinical studies and in vitro primary cell
work and murine models.
Open Access
Scan to access more
free content
Key messages
What is the key question?
▸ Is vitamin D deﬁciency a risk factor for the
development of acute respiratory distress
syndrome (ARDS)?
What is the bottom line?
▸ Patients with and at risk of ARDS are highly
likely to be deﬁcient, and severity of vitamin D
deﬁciency relates to increased epithelial
damage, the development of ARDS and
survival.
Why read on?
▸ We present evidence that an easily treatable
vitamin deﬁciency may increase the risk of
ARDS in patients at risk.
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METHODS
Patient cohorts
Patient cohort details are outlined in the online supplement but
consisted of 52 patients with ARDS, 57 patients undergoing
oesophagectomy (at risk of ARDS) and 8 patients undergoing
oesophagectomy who had high-dose vitamin D supplementation
prior to surgery.
Patients with ARDS: 52 patients who were recruited into the
ﬁrst beta agonist lung injury trial (BALTI-1) study9 and the
translational sub-study of BALTI-2.10 There was no difference in
age, sex, pre-enrolment Lung Injury score or acute physiology
and chronic health evaluation (APACHE) II in these two groups
of patients. Vitamin D levels were determined from ARDS
patient plasma collected on the day of enrolment. In the oeso-
phagectomy cohort, blood was collected on the day of the oper-
ation—pre any intervention.
Aetiology of ARDS is outlined in table 1. As these cohorts of
patients were diagnosed prior to the Berlin criteria, throughout
the paper we have used ARDS to indicate patients meeting cri-
teria for acute lung injury or ARDS according to the deﬁnition
of the American European Consensus Conference.11
Pulse Contour Cardiac Output Monitoring (PiCCO)
Extravascular lung water (EVLW) was measured using the single-
indicator transpulmonary thermodilution system (PiCCO-II;
Pulsion) as described previously.12 In our study, the coefﬁcient
of variance for this system was <7% for all parameters.
Vitamin D status: 25(OH)D3 was measured by tandem mass
spectroscopy using appropriate Vitamin D External Quality
Assessment Scheme control. 1,25(OH)2D and vitamin D binding
protein (VDBP) were measured by ELISA. Deﬁnition of vitamin
D status is controversial, with different ﬁgures used throughout
the literature, but for this study we have considered plasma
25-OH vitamin D3 levels <50 nmol/L as deﬁcient and levels
<20 nmol/L as severe deﬁciency.13 14 In addition, patients in the
at-risk cohort with 25(OH) vitamin D3 <20 nmol/L had signiﬁ-
cantly lower 1,25(OH)2 vitamin D than patients with higher
levels (<20 nmol/L 74 pmol/L vs >20 nmol/L 90 pmol/L,
p=0.029).
Murine cytokines were measured by multiplex array (R&D,
UK) or ELISA as per the manufacturer’s instruction.
ATII cell isolation and culture
ATII cells were extracted from lung resection specimens accord-
ing to the methods described previously15 (see online supple-
mentary material).
Microarray analysis is outlined in the online supplementary
material.
Wound repair, proliferation and cell death assays were per-
formed as described previously.16
Mouse methods
Wild-type (WT) C57Bl/6 mice were obtained from Harlan UK,
Oxford, UK, and maintained at BMSU, Birmingham University,
UK. Once weaned, vitamin D deﬁciency was induced in WT
pups by feeding them a vitamin D-deﬁcient chow (Harlan, USA)
for 6 weeks pre-intra-tracheal (IT) LPS. 25(OH)-vitamin D was
assessed by direct ELISA (ImmunDiagnostik, Germany). The
LPS challenge model was performed as described previously.17
Brieﬂy, mice are anaesthetised and 50 mg LPS (Sigma, UK)
instilled by IT route as a model of direct lung injury. Mice were
sacriﬁced at neutrophilic peak, 48 h post-LPS instillation, and
bronchoalveolar lavage (BAL) performed with two washes of
0.6 mL phosphate buffered saline (PBS)/EDTA (200 nM) instal-
lations to determine the local effects on inﬂammation.
Untreated controls were also analysed to determine lung para-
meters in vitamin D-deﬁcient mice. BAL ﬂuid (BALF) was
assessed for cellular inﬂammation by cell count, neutrophilia
and neutrophil apoptosis (ﬂow cytometry), markers of epithelial
damage BALF receptor for glycosylated endpoints (BALF
RAGE), protein permeability index (ratio of BALF protein:
plasma protein) as well as cytokines by luminex array (R&D
systems, UK). Results represent mice from three separate experi-
ments with at least four replicates per group. Oxygen satura-
tions were measured at 48 h post-LPS and compared with WT
mice given PBS by MouseOx II Plus (n=8 for each condition).
All experiments were performed in accordance with UK laws
with approval of local animal ethics committee.
Statistics Data were analysed using SPSS for Windows 16.0
(SPSS, Chicago, Illinois, USA). Data were tested for normality
and analysed by unpaired t tests or Mann–Whitney U test. Data
are expressed as mean (SD) unless otherwise indicated. A χ2 or
Fisher’s exact test was used to compare proportions.
Table 1 Comparison of demographics between ARDS and at-risk patients who were undergoing oesophagectomy
ARDS (n=52) At risk (n=65) p Value
Male, n (%) 30 (57) 57 (87.6) <0.001
Age (years), mean (SD) 61.3 (16.7) 62.8 (10.8) 0.560
Predisposing condition, n (%) Pneumonia 18 (35)
Other sepsis 24 (46)
Aortic aneurysm repair 3 (6)
Chest trauma 2 (3.8)
Pancreatitis 1 (1.9)
Transfusion-related lung injury 1 (1.9)
Other 3 (6)
Oesophagectomy 65 (100) n/a
LIS, median (IQR) 2.75 (2.50–3.19) 1.5 (1.0–2.0) <0.001
APACHE II median (IQR) 24 (19–28) 12 (8–14) <0.001
Worst P/F ratio during admission, mean (SD) 14.9 (5.2) 31.5 (9.9) <0.001
Hospital survival, n (%) 16 (30.8) 62 (95.4) <0.001
Length of hospital stay for survivors (days), median (IQR) 35 (16–49) 17 (10–28) 0.025
Statistical tests used are χ2 t test where data is normally distributed and Kruskal–Wallis for non-parametric data.
APACHE, acute physiology and chronic health evaluation; ratio of arterial oxygen tension to the fraction of inspired oxygen (Pao2:Fio2), arterial oxygen tension: fractional inspired
oxygen; ARDS, acute respiratory distress syndrome; LIS, lung injury score.
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To test the hypothesis that low 25(OH)D levels are associated
with the development of ARDS in the at-risk oesophagectomy
cohort (N=65), we performed multivariable logistic regression
with the exposure of interest being 25(OH)D3 level <20 nmol/L
and ARDS as the outcome. Adjusted ORs were estimated by multi-
variable logistic regression models with inclusion of covariate
terms chosen, a priori, thought to be plausibly associated with
both 25(OH)D3 level and ARDS in the oesophagectomy patient
cohort. We sought to build a parsimonious model that did not
unnecessarily adjust for covariates that did not affect bias or the
causal relation between exposure and outcome. Model calibration
was assessed using the Hosmer–Lemeshow (HL) χ2 goodness-of-ﬁt
test and the accompanying p value. Bayesian information criterion
and Akaike information criterion were also used to determine
global model ﬁt. Covariates included in the logistic regression
model were age, gender, diagnosis, staging and pack-years
smoked. The discriminatory ability for ARDS was quantiﬁed using
the c-statistic. In all analyses, p values are two-tailed and values
below 0.05 were considered statistically signiﬁcant.
RESULTS
Plasma vitamin D status in patients with or at risk of ARDS
Patients with ARDS (100%) were vitamin D-deﬁcient (plasma
25(OH)D3 <50 nmol/L). In total, 55 (96%) out of 57
unsupplemented oesophagectomy patients at risk of ARDS were
deﬁcient preoperatively but levels were higher than in patients
with ARDS. Both patients at risk and patients with ARDS had
signiﬁcantly lower levels of 25(OH)D3 than normal controls
(see ﬁgure 1). Demographics of patients groups based on
vitamin D levels are illustrated in table 2.
In at-risk patients, preoperative median plasma levels of 25
(OH)D3 were signiﬁcantly lower in those patients who were ven-
tilated with ARDS postoperatively (ARDS 16.97 nmol/L vs no
ARDS 25.46 nmol/L, p=0.014). Oesophagectomy patients with
severe vitamin D deﬁciency (plasma 25(OH)D3 <20 nmol/L)
had a 37.5% risk of postoperative lung injury as opposed to a
15% risk with vitamin D levels >20 nmol/L (ﬁgure 2).
In the at-risk oesophagectomy cohort, preoperative vitamin D
status was the only measure to have a signiﬁcant difference in
oesophagectomy patients who develop lung injury postopera-
tively (see table 3).
The odds of ARDS in patients with 25(OH)D3 <20 nmol/L
was 3.5-fold that of patients with 25(OH)D3 ≥20 nmol/L
(OR=3.5 (95% CI 1.06 to 11.6; p=0.040)). Following adjust-
ment for gender, age, diagnosis, staging data, and pack-years,
patients with 25(OH)D3 <20 nmol/L had a 4.2-fold higher
odds of ARDS than patients with 25(OH)D <20 nmol/L
(OR=4.2 (95% CI 1.13 to 15.9; p=0.032)). The adjusted
model showed good calibration (HL χ2 11.10, p=0.20) and dis-
crimination for ARDS (area under the curve 0.73). When 25
(OH)D was analysed with logistic regression as a continuous
Figure 1 Plasma 25(OH)D3 levels in acute respiratory distress
syndrome (ARDS) versus at risk and normal controls. The horizontal bar
represents the median, and the boxes represent IQRs. Vertical lines
show minimum–maximum range. Fifty-two patients with ARDS, 57
at-risk patients undergoing oesophagectomy, 18 healthy controls.
Table 2 Comparison of demographics between patients with severe deficiency, moderate deficiency and vitamin D supplemented at-risk
patients undergoing oesophagectomy
Patients with severe
25-OH vitamin D3
deficiency (n=25)
Patients with moderate
25-OH vitamin D3
deficiency (n=32)
Patients who received
vitamin D supplementation
(n=8) p Value
Male, n (%) 21 (84) 28 (87.5) 8 (100) 0.706
Age, years
median (IQR)
60.0 (52.0–68.5) 65.5 (54.5–72.0) 68.0 (63.8–71.3) 0.122
BMI median (IQR) 24.3 (20.6–27.9) 25.4 (21.7–28.3) 24.1 (22.0–26.6) 0.698
ASA median (IQR) 2.0 (2.0–2.0) 2.0 (2.0–2.0) 2.0 (2.0–2.75) 0.950
Postoperative P/F ratio 41.0 (34.3–53.3) 39.8 (32.0–52.0) 47.8 (39.4–50.8) 0.476
Preoperative plasma 25-OH vitamin D3 level (nmol/L)
median (IQR)
13.7 (10.9–16.7) 27.6 (22.5–34.9) 66.9 (42.5–92.6) <0.001
All p values shown are Kruskal–Wallis tests from SPSS.
ASA, American Society of Anaesthesiologists physical status classification system; BMI, body mass index.
Figure 2 Risk of postoperative acute respiratory distress syndrome in
severe 25(OH)D3 deﬁciency versus less severe deﬁciency. Severe
deﬁciency (n=25), less severe (n=32).
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exposure in 1 nmol/L increments, the odds of ARDS decreases
by 17% for every 1 nmol/L decrease in 25(OH)D (OR 0.83
(95% CI 0.69 to 0.98; p=0.033)), adjusted for age, gender,
diagnosis, staging and pack-years smoked.
Plasma levels of 1,25(OH)2D are lowest in ITU non-survivors
Median plasma 1,25(OH)2D levels were also signiﬁcantly lower
in patients with ARDS (35.5 pmol/L) than in at-risk patients
(85 pmol/L, p=0.0001). Plasma 1,25(OH)2D was lower at
admission to intensive therapy unit (ITU) in patients who died
than survivors (ﬁgure 3). Plasma levels of 1,25(OH)2D were
lower in oesophagectomy patients at risk of ARDS who subse-
quently went on to be ventilated for ARDS (68 pmol/L (IQR
47–91)) than those who did not get postoperative ARDS
(89 pmol/L (IQR 76–109), p=0.007).
Plasma VDBP levels are lower in patients with ARDS.
25(OH)D3 circulates tightly bound to the VDBP (also known as
Gc-actin).18 VDBP levels were 40 mg/dL in normal controls,
19 mg/dL in ARDS and 28.7 mg/mL in the at-risk patients at the
beginning of oesophagectomy (ﬁgure 4).
Vitamin D levels and perioperative changes in epithelial
integrity in patients at risk of ARDS
We measured perioperative changes in an in vivo measure of the
integrity of the alveolar–capillary barrier, namely EVLW accu-
mulation (extravascular lung water index (EVLWI)) and pulmon-
ary vascular permeability index (PVPI) using a PiCCO2
catheter19–22 and related this to the patient’s vitamin D status.
Severe vitamin D deﬁciency (25-(OH)D3 <20 nmol/L) was
associated with an increased accumulation of EVLW as assessed
by PiCCO EVLWI and evidence of increases of PVPI, a marker
of alveolar capillary permeability. Patients supplemented with
Table 3 Univariate analysis of predictors of postoperative ARDS in patients undergoing oesophagectomy
Patients with ARDS (n=15) Patients without ARDS (n=50) p Value
Male, n (%) 14 (93) 43 (86) 0.448
Age (years), median (IQR) 61 (53–66) 66 (56–71) 0.304
BMI (kg/cm2), median (IQR) 25.2 (23.9–29.1) 24.8 (21.6–28.1) 0.460
FEV1 (L), median (IQR) 2.69 (2.28–3.50) 2.85 (2.38–3.3) 0.901
FVC (L), median (IQR) 4.3 (3.4–5.2) 4.1 (3.5–4.7) 0.450
Tumour type=adenocarcinoma, n (%) 12 (80) 35 (70) 0.511
Tumour stage, n (%)*
T2 4 (27) 12 (24) 0.865
T3 11 (73) 37 (76)
N0 3 (20) 12 (24) 0.719
N1–2 12 (80) 37 (76)
Smoker, n (%)
Current 6 (40) 11 (22) 0.304
Former 7 (47) 34 (68)
Never 2 (13) 5 (10)
Pack-years, median (IQR) 30 (20–40) 30 (15–45) 0.740
Plasma 25-OH vitamin D3 (nmol/L), Median (IQR) 16.97 (12.98–22.46) 25.46 (17.35–39.77) 0.014
Plasma 1,25(OH)2 vitamin D (pmol/L), median (IQR) 68 (47–91) 89 (76–109) 0.007
Only preoperative 25(OH)D3 and 1,25(OH)2D vitamin D were significantly different in univariate analysis.
*No lung function available for seven patients, pack-years not available for two patients. One patient (without lung injury) had a benign tumour—not included in staging data.
ARDS, acute respiratory distress syndrome; BMI, body mass index.
Figure 3 Plasma 1,25(OH)2D was signiﬁcantly higher in patients with
acute respiratory distress syndrome who survived at least 28 days
following admission than those who died. The horizontal bar represents
the median, and the boxes represent IQRs. Vertical lines show
minimum–maximum range. Died (n=32), survived (n=20).
Figure 4 Plasma vitamin D binding protein measured by ELISA in
acute respiratory distress syndrome (ARDS) versus at risk and normal
controls. Fifty-two patients with ARDS, 57 at-risk patients undergoing
oesophagectomy, 18 healthy controls.
620 Dancer RCA, et al. Thorax 2015;70:617–624. doi:10.1136/thoraxjnl-2014-206680
Critical care
vitamin D prior to oesophagectomy had signiﬁcantly reduced
changes in PiCCO EVLWI and PVPI than unsupplemented
patients (ﬁgures 5 and 6).
Vitamin D deﬁciency is a determinant of inﬂammation and
epithelial injury in the intratracheal LPS murine model of
ALI/ARDS
We studied the response to 50 mg of IT LPS in WT or mice
made vitamin D deﬁcient by dietary manipulation. Deﬁcient
mice were fed a vitamin D-free diet for 6 weeks and had
median plasma vitamin 25(OH)D3 levels of 8 nmol/L (SEM
1.15 nmol/L) vs 42 nmol/L (SEM 2.17 nmol/L) in WT
(p=0.001). Untreated vitamin D-deﬁcient mice had no observed
lung damage or inﬂammation (ﬁgure 7, and data not shown).
Following LPS challenge, vitamin D-deﬁcient mice had
increased evidence of alveolar epithelial damage as measured by
BALF RAGE and BALF permeability index (ﬁgure 7A). Cellular
inﬂammation and neutrophil apoptosis in BALF were also ele-
vated in vitamin D-deﬁcient mice, along with release of proin-
ﬂammatory cytokines tumour necrosis factor-α, CXCL1/KC and
vascular endothelial growth factor (ﬁgure 7B and C, respect-
ively). These changes resulted in signiﬁcantly lower oxygen sat-
uration as measured by pulse oximetry (ﬁgure 7C), which we
have previously demonstrated as a physiological measure of
murine lung function.15
Vitamin D is trophic for alveolar epithelial cells in vitro
ATII cells were treated with 100 nmol/L of 25(OH)D3 for 24 h.
Microarray analysis revealed that vitamin D treatment caused a
sustained activation or inhibition of 660 genes that included
pathways involved in vitamin metabolism as well as regulators
of cell growth, differentiation and response to wounding
(GEOSET record GSE46749). The online supplementary table
SA and SB outline the top 25 genes up-regulated and down-
regulated by vitamin D and a heat map illustrating up-regulated
and down-regulated genes. Table 4 outlines the biological pro-
cesses and molecular functions modiﬁed by vitamin D treat-
ment. Several of the identiﬁed pathways had signiﬁcant
relevance to proliferation, wound repair and apoptosis, so we
tested the functional effects of vitamin D upon these important
repair/protective processes.
Effect of physiologically relevant doses of 25(OH)D3 upon
primary human alveolar type II cells
25(OH)D3 at physiologically relevant concentrations stimulated
scratch wound repair, cell proliferation and attenuated soluble
Fas ligand (sFasL)-mediated cell death (see ﬁgures 8–10).
DISCUSSION
We have assessed the vitamin D status of a large cohort of
patients with ARDS and a well-characterised group of patients
at risk of ARDS, namely patients undergoing oesophagectomy.
In ARDS cases, vitamin D deﬁciency was ubiquitous. Survivors
of ARDS had signiﬁcantly higher levels of vitamin D than
non-survivors.
Our ﬁnding of a 30% reduction in VDBP in patients with
ARDS supports a role for either reduced production or
increased losses as an explanation for some of the degree of
deﬁciency seen. Equally the low observed levels of circulating
1,25(OH)2D in patients with ARDS suggests a problem with
renal metabolism as this is probably the major source of circulat-
ing 1,25(OH)2D.
23
Several studies have suggested that vitamin D deﬁciency may
be a risk factor for adverse outcome in pneumonia24 and lower
respiratory tract infections in neonates.25 Other studies have
suggested patients with sepsis have signiﬁcant vitamin D deﬁ-
ciency.26 27 Our data suggests in the high-risk oesophagectomy
group that vitamin D status is also a pre-existing risk factor for
ARDS—especially when deﬁciency is severe. Patients undergo-
ing oesophagectomy with severe preoperative vitamin D deﬁ-
ciency had greater risk of postoperative ARDS and increases in
PiCCO measures of alveolar permeability than those with less
severe deﬁciency.
In our animal model of LPS-induced lung injury, vitamin D
deﬁciency was associated with greater BALF cellular inﬂamma-
tion and cytokine release at 48 h. Increased epithelial damage
and accumulation of apoptotic neutrophils was also evident.
Mice that were vitamin D deﬁcient became more hypoxic, sug-
gesting physiologically worse lung injury.
Our animal data is in keeping with recently published data in
hamsters treated with LPS.28 In contrast, Klaff et al found
reduced neutrophil chemotactic potential to the chemokine KC
ex vivo in mice deﬁcient in vitamin D but no differences in
LPS-induced BALF neutrophilia. They used a 72 h time point
Figure 5 Changes in extravascular lung water index (EVLWI) at the
end of oesophagectomy and on the morning of postoperative day 1.
EVLWI was measured using Pulse Contour Cardiac Output Monitoring II
catheter at the end of the operation and on the morning after the
operation (day 1). Severe deﬁcient (n=25), moderate (n=32) and
supplemented (n=8).
Figure 6 Changes in Pulse Contour Cardiac Output Monitoring
pulmonary vascular permeability index (PVPI) at the end of
oesophagectomy and the morning of postoperative day 1. Severe
deﬁcient (n=25), moderate (n=32) and supplemented (n=8).
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and a much lower dose of LPS (2.5 mg), which we suggest
accounts for the differences with our study.
In both our human at-risk patients and the murine model, we
have demonstrated evidence of increased permeability of the
alveolar capillary barrier in response to one lung ventilation
(EVLWI and PVPI) and LPS challenge respectively (PPI) when
severe deﬁciency is present, suggesting that vitamin D might
have protective effects on the alveolar epithelium as well as
being anti-inﬂammatory. 1,25(OH)2D has been shown to induce
DNA incorporation in human alveolar type II cells,29 but the
effects of physiologically relevant doses of 25(OH)D have not
been addressed upon type II cells previously. To address
whether 25(OH)D3 has effects on ATII cells, we demonstrated
considerable functional activity of a physiological dose of 25
(OH)D3 by microarray analysis. Physiologically relevant doses
of 25(OH)D3 stimulated wound repair, cellular proliferation
and reduced sFasL-induced cell death. These in vitro experi-
ments suggest that 25(OH)D3 may play a trophic role on adult
human alveolar epithelial cells.
This study has limitations. First, although we obtained blood
from patients with ARDS as soon as possible following admis-
sion to ITU, we are unable to be sure that levels of 25(OH)D3
were low prior to the development of ARDS in that cohort or
whether levels fall because of the development of ARDS.
Second, our at-risk data from oesophagectomy patients has to
be divided into severe deﬁciency and moderate deﬁciency
because of the severity of vitamin D deﬁciency observed in that
patient group. Third, our data in oesophagectomy patients’
needs validating in an additional signiﬁcant cohort as well as in
other patient groups at risk of ARDS. Finally, our comparison of
EVLWI between our patients in BALTI prevention cohort versus
our oesophagectomy patients in the open label vitamin D
replacement study is a potential limitation. However, the trans-
lational protocol of assessments and the two centres in which
those assessments were performed was the same between the
two studies. We are currently conducting a randomised placebo
controlled trial to conﬁrm these results due to ﬁnish recruitment
in mid-2015, which should further address this question.30
Figure 7 Lung injury and inﬂammation was signiﬁcantly higher in vitamin D-deﬁcient mice compared with wild-type (WT) following intra-tracheal
(IT)-lipopolysaccharide (LPS). Levels of tumour necrosis factor-α and CXCL1/KC in UTCs were below the detection threshold of the assays performed.
UTC, untreated control; N.D., not detected.
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Taken together, these data suggest that vitamin D deﬁciency is
ubiquitous in patients with ARDS and relates to adverse
outcome. In patients undergoing oesophagectomy, severe pre-
operative deﬁciency is associated with evidence of increased
alveolar epithelial damage and EVLWaccumulation as well as an
increased risk of postoperative lung injury. Novel in vitro data
further suggest a trophic and antiapoptotic role of physiologic-
ally relevant doses of 25(OH)D3 upon primary adult human
alveolar epithelial cells. Finally, preoperative restoration of
vitamin D levels in patients with oesophageal cancer who are at
risk of ARDS resulted in signiﬁcantly less accumulation of
EVLW than in unsupplemented patients postoperatively.
In conclusion, we suggest that clinical strategies should be
developed to replete vitamin D levels in patients at risk of
ARDS and this approach might also have value as a treatment
for established ARDS.
Table 4 List of 30 statistically significant gene ontology (GO)
terms implicated by differential expression of genes in day 3
epithelial (type II like) cells treated with vitamin D3 100 nM relative
to untreated cells
GO
Annotated
genes Total p Value
587 2230
Immune response 48 76 0.00000
Immune system process 58 103 0.00000
Cytokine activity 25 36 0.00001
Extracellular process 45 86 0.00003
Signal transducer activity 75 173 0.00008
Molecular transducer activity 75 173 0.00008
Plasma membrane 133 356 0.00013
DNA replication 20 29 0.00015
Receptor activity 57 124 0.00015
Defence response 42 83 0.00015
Monoxygenase activity 12 13 0.00018
ATPase activity, coupled to transmembrane
movement of substances
6 107 (0.00018)
Primary active transmembrane transporter
activity
6 107 (0.00018)
Hydrolase activity, acting on acid
anhydrides, catalysing transmembrane
movement of substances
6 107 (0.00018)
P-P-bond-hydrolysis-driven transmembrane
transporter activity
6 107 (0.00018)
ATPase activity, coupled to movement of
substances
6 107 (0.00018)
Cell surface receptor linked signal
transduction
69 162 0.00025
Chemotaxis 14 17 0.00027
Taxis 14 17 0.00027
Response to external stimulus 50 108 0.00030
Response to wounding 38 76 0.00043
Heme binding 12 14 0.00060
Tetrapyrrole binding 12 14 0.00060
Cellular biosynthetic process 15 145 (0.00105)
Biosynthetic process 29 214 (0.00121)
Extracellular region part 58 137 0.00168
Nucleotide biosynthetic process 1 61 (0.00168)
Cell cycle process 44 97 0.00208
Nucleobase-containing small molecule
metabolic process
3 69 (0.00412)
Nucleotide metabolic process 3 68 (0.00466)
p values of underrepresented GO terms are denoted in parentheses.
Figure 8 Scratch wound repair response of primary human alveolar
type II cells to 25(OH)D3. Wound area after 24 h was compared with
baseline and expressed as fold change in wound area. Data represents
experiments using cells from six separate lung resection specimens.
Analysis of variance p=0.001.
Figure 9 Proliferation of primary human ATII cells in response to
physiological doses of 25(OH)D3 by bromodeoxyuridine incorporation.
Experiments were performed using cells from four donors. Analysis of
variance p=0.001.
Figure 10 Cellular response to soluble Fas ligand (sFasL) 10 ng/mL
induced cell death. Experiments were performed using ATII cells from
four donors. 100 nmol/L 25(OH)D3 was added at the time of addition
of sFasL.
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